
Advanced Oncotherapy expected to disrupt the market says Hardman & Co (LON:AVO)
Hardman and Co’s Dr Martin Hall discusses Advanced Oncotherapy plc in this exclusive interview with DirectorsTalk.
Hardman and Co’s Dr Martin Hall discusses Advanced Oncotherapy plc in this exclusive interview with DirectorsTalk.
Liberum’s Anubhav Malhotra discusses Accrol Group Holdings plc in this exclusive interview with DirectorsTalk.
Edison Group’s Robert Murphy discusses BlackRock Greater Europe Investment Trust in this exclusive interview with DirectorsTalk.
Hardman and Co’s Dr Martin discusses Shield Therapeutics plc in this exclusive interview with DirectorsTalk.
Hardman & Co’s Mark Thomas discusses Oakley Capital Investments Limited in this exclusive interview with DirectorsTalk.
Valeura Energy’s Sean Guest discusses the acquisition of several assets in the Gulf of Thailand, how they are financing the deal, decommissioning obligations and growth opportunities in the portfolio in this exclusive interview with DirectorsTalk.
S-Ventures’ Scott Livingston discusses the acquisition of Juvela, the synergies with their other brands, the progress of their other brands and what investors can expect from the group in 2023 in this exclusive interview with DirectorsTalk.
Hardman and Co’s Dr Brian Moretta discusses Fidelity Special Values plc in this exclusive interview with DirectorsTalk.
Saietta Group’s Vic Kist and Tony Gott discuss a shift in strategy, ConMet collaboration, progress since IPO, its first major OEM contract, the target market, their Sunderland factory and the key milestone investors should look out for in 2023 in this exclusive interview with DirectorsTalk.
Touchstone Exploration’s Paul Baay discusses how the funds from the recent raise will be used, rate of production at Coho, capacity at the Shell pipeline, plans for the rig deployment and their 2023 goals & exploration plans in this exclusive interview with DirectorsTalk.